Adaptive Phage Therapeutics logo

Adaptive Phage Therapeutics Funding & Investors

Gaithersburg, MD

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been β€œfixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to beco... Read more

aphage.com

Total Amount Raised: $131,684,384

Adaptive Phage Therapeutics Funding Rounds

  • Series B

    $12,000,000

    Series B Investors

    AMR Action Fund
    Deerfield Capital Management
  • Grant

    $5,000,000

    Grant Investors

    Defense Health Agency
  • Series B

    $20,000,000

    Series B Investors

    AMR Action Fund
  • Series B

    $40,750,000

    Series B Investors

    Deerfield Management
    Mayo Clinic
  • Convertible Note

    $6,175,000

    Convertible Note Investors

    Mayo Clinic
  • Grant

    $33,000,000

    Grant Investors

    Department Of Defense
  • Series Unknown

    $7,000,000

    Series Unknown Investors

    Alexandria Venture Investments
  • Debt Financing

    $6,994,388

  • Seed

    $765,000

Funding info provided by Diffbot.